Carisma Therapeutics (CARM) Competitors $1.00 +0.03 (+3.09%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CARM vs. XGN, CTSO, TXMD, AWH, SNSE, IXHL, SGMT, BDTX, LFVN, and CKPTShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Exagen (XGN), Cytosorbents (CTSO), TherapeuticsMD (TXMD), Aspira Women's Health (AWH), Sensei Biotherapeutics (SNSE), Incannex Healthcare (IXHL), Sagimet Biosciences (SGMT), Black Diamond Therapeutics (BDTX), LifeVantage (LFVN), and Checkpoint Therapeutics (CKPT). These companies are all part of the "medical" sector. Carisma Therapeutics vs. Exagen Cytosorbents TherapeuticsMD Aspira Women's Health Sensei Biotherapeutics Incannex Healthcare Sagimet Biosciences Black Diamond Therapeutics LifeVantage Checkpoint Therapeutics Carisma Therapeutics (NASDAQ:CARM) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking. Is CARM or XGN more profitable? Exagen has a net margin of -30.56% compared to Carisma Therapeutics' net margin of -350.08%. Exagen's return on equity of -78.90% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-350.08% -344.89% -88.02% Exagen -30.56%-78.90%-31.77% Does the media favor CARM or XGN? In the previous week, Carisma Therapeutics had 5 more articles in the media than Exagen. MarketBeat recorded 5 mentions for Carisma Therapeutics and 0 mentions for Exagen. Carisma Therapeutics' average media sentiment score of 0.50 beat Exagen's score of 0.00 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Positive Exagen Neutral Does the MarketBeat Community favor CARM or XGN? Exagen received 6 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 54.05% of users gave Exagen an outperform vote. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes14100.00% Underperform VotesNo VotesExagenOutperform Votes2054.05% Underperform Votes1745.95% Do analysts rate CARM or XGN? Carisma Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 600.00%. Exagen has a consensus price target of $7.00, suggesting a potential upside of 172.37%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Exagen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, CARM or XGN? Carisma Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Which has stronger valuation and earnings, CARM or XGN? Exagen has higher revenue and earnings than Carisma Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$14.92M2.78-$86.88M-$1.78-0.56Exagen$52.55M0.85-$23.69M-$0.97-2.65 Do institutionals & insiders believe in CARM or XGN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Comparatively, 26.1% of Exagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCarisma Therapeutics and Exagen tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.54M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.569.93115.5615.18Price / Sales2.78381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book1.525.324.665.02Net Income-$86.88M$153.56M$119.06M$225.46M7 Day PerformanceN/A0.11%0.80%0.37%1 Month Performance3.53%15.22%5.65%3.57%1 Year Performance-66.78%41.14%36.76%29.44% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics2.6058 of 5 stars$1.00+3.1%$7.00+600.0%-65.6%$41.54M$14.92M-0.5620Analyst UpgradeNews CoverageGap UpXGNExagen4.1971 of 5 stars$2.57+5.8%$7.00+172.4%+48.6%$44.69M$52.55M-2.65220Negative NewsCTSOCytosorbents1.9 of 5 stars$1.00-1.0%$2.00+100.0%-32.0%$54.43M$36.35M-1.89186Upcoming EarningsAnalyst ForecastNews CoverageTXMDTherapeuticsMD0.8331 of 5 stars$1.56+0.6%N/A-26.1%$17.99M$996,000.000.00420AWHAspira Women's Health1.1844 of 5 stars$0.90flat$4.40+388.9%-80.8%$14.45M$9.15M-0.62110Analyst ForecastGap UpSNSESensei Biotherapeutics4.3577 of 5 stars$0.49+3.2%$4.33+784.2%-40.2%$12.33MN/A-0.4240Upcoming EarningsHigh Trading VolumeIXHLIncannex Healthcare0.9939 of 5 stars$2.59+14.1%N/A+148.8%$164.41M$10,000.000.003Gap UpSGMTSagimet Biosciences2.4607 of 5 stars$5.33+3.5%$24.00+350.3%+50.1%$163.47M$2M0.008Analyst ForecastNews CoverageBDTXBlack Diamond Therapeutics2.2329 of 5 stars$2.89+5.5%$15.50+436.3%+56.6%$163.31MN/A-1.9390Upcoming EarningsShort Interest ↑LFVNLifeVantage3.2054 of 5 stars$13.00+6.4%N/A+72.0%$162.76M$200.16M40.63260Earnings ReportDividend AnnouncementShort Interest ↑News CoverageCKPTCheckpoint Therapeutics3.4135 of 5 stars$3.51+2.0%$12.00+241.9%+90.8%$158.01M$78,000.00-1.8510Short Interest ↑Gap Down Related Companies and Tools Related Companies Exagen Alternatives Cytosorbents Alternatives TherapeuticsMD Alternatives Aspira Women's Health Alternatives Sensei Biotherapeutics Alternatives Incannex Healthcare Alternatives Sagimet Biosciences Alternatives Black Diamond Therapeutics Alternatives LifeVantage Alternatives Checkpoint Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
